San Francisco company ValGenesis is a pioneer in paperless enterprise validation lifecycle management solutions. Founded in 2005, their VLMS tool has proven effective for managing equipment, instruments, computer systems, cleaning, analytical methods, and process validation. The company also claims that automation of the validation process decreases the cost and time taken to complete the validation cycle by at least "40 to 50%."
Now, the company has announced that a global pharma giant based in Japan has tapped ValGenesis to digitalize its validation lifecycle process in Europe, and eventually across its facilities around the world. The Japanese company hopes to address new business challenges and opportunities using ValGenesis to guide its future plans.
"This is a noteworthy win for ValGenesis as we onboard yet another Japanese pharma giant," Narayan Raj, Senior Vice President of Global Sales & Operations at ValGenesis said in a statement. "By choosing our SaaS-based platform to manage the validation lifecycle process across their global sites, this client will be able to meet stringent validation requirements and enable data integrity governance while accelerating the development and manufacture of innovative new drugs in Japan and across the globe,"
This comes as the company looks to expand its operations worldwide. Notably, the company established a subsidiary in Ontario, Canada in 2019.
At the beginning of 2020, Valgenesis announced that a global integrated pharmaceutical company had chosen its paperless VLMS to manage the corporate validation lifecycle process across multiple sites. While it didn't disclose the company’s name, ValGenesis revealed that the global firm offers over 190 medications, 60 active pharmaceutical ingredients (APIs) for drug manufacture, diagnostic kits, critical care, and biotechnology products. The company also offers a portfolio of services that cover major therapeutic areas such as gastrointestinal, cardiovascular, diabetology, oncology, pain management, and dermatology.
In 2018, global software company Infosys partnered with ValGenesis to enhance digitization in life sciences. Under the partnership, Infosys integrated the ValGenesis VLMS within its suite of services for the pharmaceutical and biotech industries, to be presented in a secure cloud setting.
According to data from Crunchbase, ValGenesis raised $400,000 in a single funding round in July 2017.
